The Recent Success
Back in January of 2013, Austin, Texas based biotechnology focused company Mirna Therapeutics confirmed that they would have a new member joining their Board of Directors. This new member was revealed to be Dr. Clay Siegall, the CEO and co-founder of Seattle Genetics who would be serving as an outside director. Mirna Therapeutics made this decision based upon their current focus on cancer research, which Dr. Siegall has plenty of experience in. Dr. Paul Lammers, the President and CEO of Mirna Therapeutics, commented on the announcement saying that they were enthusiastic having someone who has the experience that Dr. Siegall has joining their Board of Directors. Dr. Lammers has also stated his expectation of Dr. Siegall helping Mirna Therapeutics in the development of their microRNA-based therapeutics.
About Dr. Siegall
Dr. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, CEO, and Chairman of the Board of Directors. It was under Dr. Siegall’s leadership that enabled Seattle Genetics to grow and become what it is today. After all, it was thanks to Dr. Siegall’s financial strategies that enabled the company to secure more than $675 million from both public and private finances. Before founding Seattle Genetics, Dr. Siegall had been part of the National Cancer Institute, National Institutes of Health (1988-1991) and then later the Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997). Dr. Siegall received his PhD in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.
About Seattle Genetics
Incorporated on July 15, 1997, the Bothell, Washington based company has been focused upon antibody based cancer treatment methods. Currently the most renown product of the company is the Brentuximab vedotin, better known under the trade name of Adcetris, which is an antibody-drug conjugate that targets the CD30 protein. Other antibody-drug conjugates from Seattle Genetics include SGN-CD19A, SGN-CD33A, SGN-LIV1A, and SGN-CD70A while ASG-22ME and ASG-15ME are still in development and being worked upon in collaboration with the company Agensys. Currently, Seattle Genetics has around 650 employees within the United States.